MOUNTAIN VIEW, Calif., Nov. 13 /PRNewswire/ -- Based on its recent analysis of the drug eluting stents (DES) market, Frost & Sullivan recognizes Boston Scientific with the 2008 North American Frost & Sullivan Market Leadership Award. This award highlights important milestones for Boston Scientific, including FDA approvals for the PROMUS(TM) Everolimus-Eluting Coronary Stent System, the TAXUS(R) Express2(TM) Atom(TM) Stent and the company’s second-generation TAXUS(R) Liberte(R) Stent. These product approvals enable Boston Scientific to deliver the industry’s only two-drug stent portfolio as well as the largest size matrix available and reflect on Boston Scientific’s commitment to delivering to patients the widest array of solutions in treating coronary artery disease.
The TAXUS Express2 Atom Paclitaxel-Eluting Coronary Stent System is one example of Boston Scientific working to expand treatment options to benefit patients. TAXUS Atom was approved by the Food and Drug Administration (FDA) on September 25, 2008, making it the first DES approved for the treatment of small coronary vessels. Currently, clinicians are resigned to using either bare-metal stents, which pose risk of restenosis, or a partially expanded DES. The TAXUS Express2 Atom, offers clinicians a more targeted solution that fulfills the size requirements of that anatomy, while reducing the risk of restenosis. That same day the FDA also announced the approval of the TAXUS(R) Express2(TM) for the treatment of in-stent restenosis in bare-metal stents. Both approvals expand indications for use for physicians and expand treatment options for patients.
“Although only introduced in 2003, drug eluting stents have reshaped the entire cardiovascular industry in just a few short years,” says Frost & Sullivan Research Analyst Archana Swathy. “These devices are taking percutaneous coronary intervention to new heights, addressing many of the concerns and issues restricting the availability of care in the past.”
Data surrounding potential safety risks associated with DES and possible late stent thrombosis had resulted in lower usage in late 2006-07. Recognizing the importance of clinical data, Boston Scientific addressed the need of physicians for additional DES safety information and continues to provide effective data that reinforce its leadership position in the DES arena. Earlier this year, Boston Scientific reported encouraging one-year data from the SYNTAX trial that compared percutaneous coronary intervention (PCI) using the TAXUS Express2 paclitaxel-eluting coronary stent system to contemporary coronary artery bypass graft surgery (CABG). The TAXUS stent systems have been evaluated by the industry’s most extensive randomized, controlled clinical trial program, supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, approximately 4.6 million TAXUS stents have been implanted globally, making them the world’s most frequently used drug-eluting stents.
In addition to its intense focus on evidence-based medicine and a robust clinical trial program, Boston Scientific has introduced the Stentplus(TM) program to enhance patient outcomes post PCI by improving patient compliance with physician-prescribed, dual anti-platelet therapy. This comprehensive program specifically targets DES patients, regardless of the stent brand.
It is endorsed by several prominent organizations, including the Society for Cardiovascular Angiography and Interventions (SCAI), and is used by nearly 1,000 hospitals and more than 160,000 patients nationwide.
Frost & Sullivan recognizes Boston Scientific’s unique capacity to establish and sustain its leadership in this highly competitive environment, and has selected the company to be the recipient of its 2008 North American Market Leadership Award for the Drug Eluting Stents Market.
Each year, Frost & Sullivan presents this award to the company that has demonstrated market share leadership through the implementation of sound market strategy. The recipient has displayed excellence in all areas of the market leadership process including the identification of market challenges, drivers, and restraints, as well as strategy development and methods of addressing these market dynamics.
Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company’s TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan’s Growth Partnership Services, visit http://www.awards.frost.com.
CONTACT: Jake Wengroff of Frost & Sullivan, +1-210-247-3806,
jake.wengroff@frost.com
Web site: http://www.frost.com/
http://www.bostonscientific.com/
